XOMA Share Price Performance
US$37.90
13.29 (54.00%)
42.4% undervalued intrinsic discount
US$65.75
Fair Value
Price US$37.90
AnalystConsensusTarget US$65.75
AnalystLowTarget US$50.00
AnalystHighTarget US$97.00
Fair ValueUS$65.75
Share Pricen/a
XOMA Royalty Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
XOMA Community Narratives
AN
Fair Value
·Fair Value US$65.75 42.4% undervalued intrinsic discount
Royalty Financing Expansion And Diversified Biotech Portfolio Will Support Long Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$50 24.2% undervalued intrinsic discount
Future Royalty Concentration And Litigation Risks May Eventually Reward Patient Holders
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$97 60.9% undervalued intrinsic discount
Expanding Royalty Portfolio And Funded Pipelines Will Reshape Long Term Earnings Quality
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Royalty Financing Expansion And Diversified Biotech Portfolio Will Support Long Term Upside
Catalysts About XOMA Royalty XOMA Royalty acquires and manages a diversified portfolio of biotechnology royalties and milestone interests across the drug development spectrum. What are the underlying business or industry changes driving this perspective?Read more
AN
US$65.75
42.4% undervalued intrinsic discount
Fair Value
Revenue
36.68% p.a.
Profit Margin
25.53%
Future PE
28.25x
Price in 2029
US$81.93
Expanding Royalty Portfolio And Funded Pipelines Will Reshape Long Term Earnings Quality
Catalysts About XOMA Royalty XOMA Royalty builds and manages a diversified portfolio of biotechnology royalty and milestone interests across the drug development cycle. What are the underlying business or industry changes driving this perspective?Read more
AN
US$97
60.9% undervalued intrinsic discount
Fair Value
Revenue
68.15% p.a.
Profit Margin
25.42%
Future PE
22.52x
Price in 2029
US$121.07
Future Royalty Concentration And Litigation Risks May Eventually Reward Patient Holders
Catalysts About XOMA Royalty XOMA Royalty aggregates biotechnology royalty and milestone interests across the drug development spectrum, aiming to build a diversified, cash generative portfolio funded largely by third party R&D spend. What are the underlying business or industry changes driving this perspective?Read more
AN
US$50
24.2% undervalued intrinsic discount
Fair Value
Revenue
6.86% p.a.
Profit Margin
13.26%
Future PE
85.61x
Price in 2029
US$62.57
Trending Discussion
Recently Updated Narratives
AN
Royalty Financing Expansion And Diversified Biotech Portfolio Will Support Long Term Upside
Fair Value: US$65.75 42.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanding Royalty Portfolio And Funded Pipelines Will Reshape Long Term Earnings Quality
Fair Value: US$97 60.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Royalty Concentration And Litigation Risks May Eventually Reward Patient Holders
Fair Value: US$50 24.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
XOMA Royalty Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 1.55
- 96.72%
- 35.51%
- 104.8%
About XOMA
- Founded
- 1981
- Employees
- 14
- CEO
- WebsiteView website
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Recent XOMA News & Updates
